Key Developments in the Potential of Curcumin for the Treatment of Peripheral Neuropathies

Caillaud, Martial; Myo, Yu Par Aung; Mckiver, Bryan; Warncke, Urszula Osinska; Thompson, Danielle; Mann, Jared; Fabbro, Egidio Del; Desmoulière, Alexis; Billet, Fabrice; Damaj, M. Imad

doi:10.3390/antiox9100950

Cited by 20 publications

(21 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clinical trial revealed that the oral administration with curcumin could significantly improve peripheral neuropathy in patients with type 2 diabetes [34,35] . The study has reported that curcumin at dose ranging from 20 to 300 mg/kg/day was administered (oral or intraperitoneal) for 7 to 140 days [36] . The median lethal dose of curcumin in rats and mice was higher than 2,000 mg/kg BW (oral) [37] .…”

Section: Resultsmentioning

confidence: 99%

Curcumin Ameliorates the Experimental Diabetic Peripheral Neuropathy through Promotion of NGF Expression in Rats

Zhang

Lin

Sun

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

Increasing evidence suggested that inhibiting the apoptosis of Schwann cells (SCs) and promoting nerve growth factor (NGF) expression in sciatic nerves play key roles in preventing the onset of diabetic peripheral neuropathy (DPN). Curcumin, a primary bioactive substance in turmeric with multiple characteristics, has been shown to have many therapeutic effects in a variety of diseases. However, curcumin is poorly studied in the DPN models. We aimed to explore the therapeutic benefits and underlying mechanism of curcumin in high fat/sugar diets joint streptozotocin (STZ)‐induced DPN rat models. Sprague‐Dawley (SD) rats were divided into five groups (6 rats per group), control group, DPN group, Curcumin groups (50, 100, and 150 mg/kg). Curcumin was administered intragastrically once per day for 4 continuous weeks. Body weight (BW) and fasting blood glucose (FBG) were monitored in all groups. The mechanical withdraw threshold (MWT) was measured. We also assessed neuropathic change by testing nerve conductance velocity (NCV) in sciatic nerves. TEM was applied to observe the sciatic nerves ultrastructure. The SCs apoptosis in sciatic nerves was stained using TUNEL kit. NGF contents in sciatic nerves and serum were detected using western blotting and ELISA analysis. The results showed curcumin had no obvious effect on the BW and FBG change. Curcumin (100 and 150 mg/kg) attenuated the MWT, NCV, and sciatic nerves ultrastructure in DPN rats. Curcumin (50, 100 and 150 mg/kg) reduced SCs apoptosis in sciatic nerves. In addition, curcumin at 150 mg/kg had the best efficacy in increasing protein expression of NGF in sciatic nerves and serum NGF level. Our work demonstrated that curcumin has neuroprotective effects for the treatment of DPN.

show abstract

Section: Resultsmentioning

confidence: 99%

Curcumin Ameliorates the Experimental Diabetic Peripheral Neuropathy through Promotion of NGF Expression in Rats

Zhang

Lin

Sun

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

show abstract

“…Clinically, painful DPN is mainly manifested as loss of skin sensation and pain in the distal extremities, of which symmetrical pain in the lower extremities is the most common (7). Other manifestations include atypical pain, numbness, acupuncture and burning sensation, and can also be manifested as other neuromotor dysfunctions, such as muscle weakness, poor balance, and tendency to fall (8). Studies have shown that up to 60% of diabetic patients are deeply affected by painful diabetes, leading to the occurrence of serious physical and social diseases, and seriously affecting the quality of life of patients (9).…”

Section: Introductionmentioning

confidence: 99%

Status of Analgesic Drugs and Quality of Life Results for Diabetic Peripheral Neuropathy in China

Lian

Cui

Zhang³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveThe purpose of this study is to describe the current clinical situation of patients with painful diabetic peripheral neuropathy (DPN) and related anxiety, depression, and the quality of life of patients in mainland China, and to report the current status of the use of analgesics.MethodsBetween June 15, 2021, and October 15, 2021, a total of 401 participants participated in the study. Recruitment was carried out using a multi-level sampling method. Participants’ demographics, medical history, analgesic use, Michigan Symptom Score (MNSI), Numerical Rating Scale (NRS) pain score, Patient Health Questionnaire 9 (PHQ-9) score, Generalized Anxiety Disorder 7 (GAD) -7) Score, quality of life score (SF-12) and diabetes treatment status were collected.ResultsAmong the participants, there were 236 male patients and female patients. Participants were 322 patients over 40 years old. Regarding the use of analgesics: 132 patients reported using analgesics, 221 patients reported not using analgesics, and 48 patients reported having used analgesics. The results of the scale showed that the scores of NRS, GAD-7, PHQ-9 and SF-12 were 5.12 ± 2.15, 6.33 ± 3.67, 8.46 ± 4.07 and 47.84 ± 19.92 for patients who used analgesics, Compared with patients who did not use analgesics (NRS: 1.99 ± 1.7, GAD-7: 1.81 ± 2.81, PHQ-9: 3.13 ± 4.10, SF-12: 78.34 ± 21.66) there are significant differences (p< 0.001). In addition, patients’ NRS scores are also closely related to GAD-7, PHQ-9 and SF-12 scores.ConclusionThe severity of symptoms, mental status and quality of life of patients who used analgesics were more severe than those of patients who did not use analgesics. Pregabalin is still the preferred analgesic for patients with painful DPN, and the use of opioids in my country is extremely low, which is consistent with current international guidelines. Age, diabetic duration, DPN duration, PHQ-9 score, GAD-7 score and SF-12 scores are closely related to NRS pain scores. In addition, there are still a considerable number of patients who have not used analgesics due to financial burdens and other reasons, suggesting that China still has insufficient pain management in DPN patients.

show abstract

“…C. domestica Valeton and C. brog Valeton) ( Zingiberaceae ) used as a culinary spice in curry powder [ 19 ]. The antioxidant and anti-inflammatory properties of curcumin [ 20 , 21 ] could be attributed to its antinociceptive activity against different pain conditions, including peripheral neuropathic, inflammatory, postoperative, burn pain, and wound healing [ 22 , 23 , 24 , 25 ], as well as its use as an oral supplement in the treatment of various inflammatory medical conditions, such as alopecia [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Curcumin and Its Different Formulations in Preclinical and Clinical Studies of Peripheral Neuropathic and Postoperative Pain: A Comprehensive Review

Basu

Maier

Basu

2021

IJMS

View full text Add to dashboard Cite

Lesion or disease of the somatosensory system leads to the development of neuropathic pain. Peripheral neuropathic pain encompasses damage or injury of the peripheral nervous system. On the other hand, 10–15% of individuals suffer from acute postoperative pain followed by persistent pain after undergoing surgeries. Antidepressants, anticonvulsants, baclofen, and clonidine are used to treat peripheral neuropathy, whereas opioids are used to treat postoperative pain. The negative effects associated with these drugs emphasize the search for alternative therapeutics with better efficacy and fewer side effects. Curcumin, a polyphenol isolated from the roots of Curcuma longa, possesses antibacterial, antioxidant, and anti-inflammatory properties. Furthermore, the low bioavailability and fast metabolism of curcumin have led to the advent of various curcumin formulations. The present review provides a comprehensive analysis on the effects of curcumin and its formulations in preclinical and clinical studies of neuropathic and postoperative pain. Based on the positive outcomes from both preclinical and clinical studies, curcumin holds the promise of mitigating or preventing neuropathic and postoperative pain conditions. However, more clinical studies with improved curcumin formulations are required to involve its use as adjuvant to neuropathic and postoperative drugs.

show abstract

Key Developments in the Potential of Curcumin for the Treatment of Peripheral Neuropathies

Cited by 20 publications

References 99 publications

Curcumin Ameliorates the Experimental Diabetic Peripheral Neuropathy through Promotion of NGF Expression in Rats

Curcumin Ameliorates the Experimental Diabetic Peripheral Neuropathy through Promotion of NGF Expression in Rats

Status of Analgesic Drugs and Quality of Life Results for Diabetic Peripheral Neuropathy in China

Effects of Curcumin and Its Different Formulations in Preclinical and Clinical Studies of Peripheral Neuropathic and Postoperative Pain: A Comprehensive Review

Contact Info

Product

Resources

About